桂林三金：BC006单抗注射液项目即将完成Ⅰ期临床试验

Core Viewpoint - Guilin Sanjin (002275) is nearing the completion of Phase I clinical trials for its product BC006 monoclonal injection, with potential key breakthroughs to be disclosed as per Shenzhen Stock Exchange requirements [1] Company Summary - The company has responded to investor inquiries on October 17, indicating progress in its clinical trials for BC006 [1]